Apollo Global Management heads into Wednesday's Q1 print with a clear tension: the Street has spent weeks slashing price targets, yet every firm with a view still rates the stock a Buy or Overweight.
The analyst picture is one of broad conviction with tightening expectations. Morgan Stanley, Goldman Sachs, and Barclays all trimmed targets in April — Goldman most aggressively, cutting from $169 to $134. Evercore ISI bucked the trend by lifting its target to $145 from $135, maintaining an Outperform. The consensus mean now rests at $139, implying roughly 7.6% upside from Monday's $129.19 close. No firm has downgraded. The direction of travel is lower estimates, not lower ratings — a distinction that matters. Bears point to the bear case directly: 2025 Spread-Related Earnings (SRE) growth expectations have been cut from ~9.5% to mid-single digits, and competitive pressures in the retail channel could shave ~10 basis points on an estimated $35–40 billion in assets from higher prepayments. Bulls counter with record retirement services inflows of $17.2 billion and $14 billion deployed at wider spreads — positioning Apollo to harvest better spreads over the coming quarters.
Short positioning does not read as particularly aggressive heading into the number. Short Interest sits at 5.5% of the free float — meaningful but stable, barely changed over the past week. Cost to borrow is a modest 0.43%, and availability has tightened modestly to its 52-week high in recent days, though absolute levels remain comfortable. Days to cover runs at 12.7 on the official FINRA count, which is elevated but reflects Apollo's liquidity profile rather than a squeeze dynamic. The ORTEX short score of 57.4 is middling — no sharp directional signal from the lending market.
Options positioning has turned notably bullish into the event. The put/call ratio has dropped to 0.86, more than 3.6 standard deviations below its 20-day average of 0.91 — the most call-skewed reading of the past year. That is a sharp departure from the cautious tone that dominated through most of April, when the PCR barely moved from 0.91. RSI-14 runs at 68, reflecting the stock's 21% recovery over the past month after a bruising start to the year; it remains down roughly 10% year-to-date. Peers CRBG and EQH posted similar weekly gains of 4.7% and 2.6% respectively, suggesting the broader alternative/insurance complex has rallied in tandem — the move in APO is not idiosyncratic.
The February print saw Apollo slip just 0.5% on the day before drifting 5.9% lower over the following five sessions, a reminder that headline beats do not automatically translate into sustained price appreciation. The Q1 report will test whether management's deployment pipeline and retirement services momentum can offset the reduced SRE growth outlook — and whether call buyers at these levels have correctly anticipated the story.
See the live data behind this article on ORTEX.
Open APO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
